Antimicrobial Agents and Chemotherapy by Campbell, Patricia J. et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2011, p. 2032–2041 Vol. 55, No. 5
0066-4804/11/$12.00 doi:10.1128/AAC.01550-10
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Molecular Detection of Mutations Associated with First- and
Second-Line Drug Resistance Compared with Conventional
Drug Susceptibility Testing of Mycobacterium tuberculosis†§
Patricia J. Campbell,‡ Glenn P. Morlock,‡ R. David Sikes, Tracy L. Dalton, Beverly Metchock,
Angela M. Starks, Delaina P. Hooks, Lauren S. Cowan,
Bonnie B. Plikaytis, and James E. Posey*
Mycobacteriology Laboratory Branch, Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis,
STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333
Received 9 November 2010/Returned for modification 3 January 2011/Accepted 31 January 2011
The emergence of multi- and extensively drug-resistant tuberculosis is a significant impediment to the
control of this disease because treatment becomes more complex and costly. Reliable and timely drug suscep-
tibility testing is critical to ensure that patients receive effective treatment and become noninfectious. Molec-
ular methods can provide accurate and rapid drug susceptibility results. We used DNA sequencing to detect
resistance to the first-line antituberculosis drugs isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and
ethambutol (EMB) and the second-line drugs amikacin (AMK), capreomycin (CAP), kanamycin (KAN),
ciprofloxacin (CIP), and ofloxacin (OFX). Nine loci were sequenced: rpoB (for resistance to RIF), katG and
inhA (INH), pncA (PZA), embB (EMB), gyrA (CIP and OFX), and rrs, eis, and tlyA (KAN, AMK, and CAP). A
total of 314 clinical Mycobacterium tuberculosis complex isolates representing a variety of antibiotic resistance
patterns, genotypes, and geographical origins were analyzed. The molecular data were compared to the
phenotypic data and the accuracy values were calculated. Sensitivity and specificity values for the first-line
drug loci were 97.1% and 93.6% for rpoB, 85.4% and 100% for katG, 16.5% and 100% for inhA, 90.6% and 100%
for katG and inhA together, 84.6% and 85.8% for pncA, and 78.6% and 93.1% for embB. The values for the
second-line drugs were also calculated. The size and scope of this study, in numbers of loci and isolates
examined, and the phenotypic diversity of those isolates support the use of DNA sequencing to detect drug
resistance in the M. tuberculosis complex. Further, the results can be used to design diagnostic tests utilizing
other mutation detection technologies.
Two critical components of tuberculosis (TB) control are
prompt identification of new cases and rapid implementation
of effective treatment regimens to interrupt transmission. The
standard treatment regimen combines four first-line antibiot-
ics, isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and
ethambutol (EMB), and renders patients with tuberculosis
noncontagious when they are properly administered. Inade-
quate treatment can select for drug-resistant bacilli (acquired
resistance), and those resistant organisms can be transmitted
to other individuals (primary resistance). Although drug resis-
tance is disconcerting, the emergence of multidrug-resistant
(MDR) TB, defined as resistance to both INH and RIF, is
especially worrisome, as it leads to more complex and costly
treatment regimens. In 2008, the World Health Organization
(WHO) estimated that there were 11.1 million cases of tuber-
culosis worldwide, of which 440,000 cases were MDR TB (43).
MDR TB complicates treatment because ineffective first-line
antibiotics must be replaced with second-line drugs that are
more costly and that can lead to more adverse side effects.
These drugs include several fluoroquinolone (FQ) compounds
as well as the injectable drugs amikacin (AMK), capreomycin
(CAP), and kanamycin (KAN). In 2006, the Centers for Dis-
ease Control and Prevention (CDC) and WHO defined exten-
sively drug-resistant (XDR) TB as MDR TB that is also resis-
tant to any FQ and one of the second-line injectable drugs (6,
41). The full extent of XDR TB is unknown because many
countries lack sufficient laboratory system capacity, especially
for diagnosis. The available data show that 5.4% of MDR TB
cases fit the XDR TB definition (43), with 55 countries or
territories reporting at least one case by the end of 2008 (42).
The control of drug-resistant TB, in any form, requires ac-
curate and prompt diagnosis of the type of resistance. The
timeliness of culture-based drug susceptibility testing (DST) is
constrained by the slow growth characteristic of Mycobacterium
tuberculosis, which can take 2 to 4 weeks, depending on the
method of testing. DST of certain drugs can also be technically
challenging and, in resource-limited areas, cost prohibitive.
The use of molecular methods to identify mutations associated
with drug resistance can decrease diagnostic delay and, in some
cases, may prove to be more specific than phenotypic DST.
The great potential of genetic testing to rapidly diagnose drug
resistance has been the impetus behind a tremendous amount
of basic and applied research. The result of this area of re-
search has been the development of numerous commercial and
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laboratory-designed diagnostic assays. These assays are in-
creasingly being used in clinical and reference laboratories.
In September 2009, our laboratory at CDC began offering a
new, Clinical Laboratory Improvement Amendments (CLIA)-
compliant reference service: DNA sequencing of drug resis-
tance-associated loci (8). Prior to implementation, to verify
this molecular detection of drug resistance (MDDR) service,
we sequenced all or part of nine loci in 314 M. tuberculosis
complex isolates. The loci were chosen on the basis of their
demonstrated association with drug resistance and included
rpoB (RIF), katG and inhA (INH), pncA (PZA), embB (EMB),
gyrA (FQ), and rrs, eis, and tlyA (second-line injectables). Pre-
vious studies comparing phenotypic DST results to molecular
data have been fragmented in scope, being focused on a lim-
ited array of loci in a comparatively small number of primarily
or exclusively drug-resistant isolates. In the study described in
this report, we analyzed a large set of clinical isolates repre-
senting a variety of antibiotic resistance patterns, including
pansusceptible, poly-drug-resistant (isolates that were resistant
to two or more drugs but that did not meet the definition of
MDR TB), MDR, and XDR isolates. The phenotypic and
genotypic results were compared to determine the specificity
and sensitivity for each locus studied.
MATERIALS AND METHODS
Bacterial strains and culture conditions. M. tuberculosis H37Rv, 60 WHO
proficiency test isolates from 2007 and 2008 (representing 30 unique patient
isolates in duplicate), and 254 stored clinical isolates (collected from 2000 to
2008) were selected from the culture collection at the Mycobacteriology Labo-
ratory Branch, Division of Tuberculosis Elimination, CDC. Samples were chosen
to represent a variety of antibiotic resistance patterns from both U.S. and non-
U.S. laboratories. The 314 isolates were grown in 5 ml of Middlebrook 7H9 broth
(7H9) supplemented with 10% (vol/vol) albumin-dextrose-catalase enrichment
(Difco Laboratories) and 0.05% (vol/vol) Tween 80 (Sigma-Aldrich) at 37°C
until they reached an approximate optical density at 600 nm of 1.0 (correspond-
ing to 5  108 CFU/ml).
Drug susceptibility testing. Antituberculosis DST was completed according to
the Clinical and Laboratory Standards Institute (CLSI) standard (24). Testing of
all clinical isolates was completed at the time of their submittal to the CDC.
Susceptibility was determined via the indirect agar proportion method utilizing
Middlebrook 7H10 agar supplemented individually with the following drugs: RIF
(1 g/ml), INH (0.2, 1, and 5 g/ml), EMB (5 g/ml), ofloxacin (OFX; 2 g/ml),
ciprofloxacin (CIP; 2 g/ml), KAN (5 g/ml), CAP (10 g/ml), and AMK (4
g/ml). PZA was tested using the Bactec 460 (100 g/ml), MGIT (100 g/ml), or
agar proportion (25 g/ml) method, on the basis of testing practices at the time
of isolate receipt.
DNA isolation, spoligotyping, amplification, and sequencing of loci. DNA was
isolated from 7H9 subcultures by mechanical cell disruption, as previously de-
scribed (23). In short, 1 ml of each subculture was transferred to a 2-ml Lysing
Matrix B tube (MP Biomedical, Inc.), heat killed, and mixed with 400 l Tris-
EDTA buffer and 400 l chloroform. The mixture was thoroughly agitated using
a FastPrep 120 apparatus (MP Biomedicals) for 20 s at a setting of 4.0. The
samples were centrifuged at 8,000  g for 5 min, and the DNA-containing
aqueous layer was collected and stored at 4°C. Families of study isolates were
determined by spoligotyping as previously described (7).
The following nine loci were amplified by PCR: rpoB (RIF), katG and inhA
(INH), embB (EMB), gyrA (FQ), rrs (KAN, CAP, and AMK), eis (KAN), tlyA
(CAP), and pncA (PZA). Of the nine loci, only the drug resistance-determining
regions of rpoB (rifampin resistance-determining region [RRDR]), embB
(ethambutol resistance-determining region [ERDR]), and gyrA (quinolone resis-
tance-determining region [QRDR]), the promoters of inhA and eis, and regions
with established resistance-associated mutations of katG and rrs were amplified
using locus-specific primers (see Table S1 in the supplemental material). The
complete open reading frames of tlyA and pncA were amplified due to the
established presence of resistance-associated mutations throughout the loci (see
Table S1 in the supplemental material). Each 25-l PCR mixture contained 12.5
l HotStarTaq master mix (Qiagen), 1.5 l of the forward and reverse 5 M
primers, 8.5 l distilled H2O (dH2O), and 1 l of genomic DNA. The amplifi-
cation parameters included an initial denaturation step at 95°C for 15 min,
followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 60°C for 30 s,
and elongation at 72°C for 30 s, with a final elongation step at 72°C for 7 min. All
primers were synthesized by the Biotechnology Core Facility at CDC (see Table
S1 in the supplemental material). PCR products were analyzed on 1.5% agarose-
Tris-EDTA gels and stained with ethidium bromide. Verified PCR products
were treated with ExoSAP-IT reagent (USB Corporation), using the manufac-
turer’s protocol, to remove unincorporated primers and nucleotides. The treated
products were then diluted 1:10 with dH2O and used as the template for DNA
sequencing.
Sequencing reactions (20-l reaction mixtures) were completed with an ABI
BigDye Terminator (version 3.1) cycle sequencing kit, and the reaction mixtures
included 4 l of BigDye Terminator (version 3.1) reagent (ABI), 2 l of 1.6 M
primer (with the same sequences as the primers used for PCR), 2 l of 5
reaction buffer (ABI), 11 l of dH2O, and 1 l of PCR template. PCR products
were sequenced with a forward primer and a reverse primer at each locus for
maximum coverage and reproducibility of results. The reactions were cycled
according to manufacturer guidelines. The unincorporated terminators were
removed from the completed reactions by treatment with a BigDye Xterminator
kit (ABI), using the manufacturer’s protocol, and were examined using an ABI
3130xl genetic analyzer with standard run conditions for electrophoresis and data
collection.
Analysis. Sequence data produced by the ABI 3130xl genetic analyzer were
reviewed for confidence levels with an ABI sequence scanner, and chromato-
grams were analyzed for the presence or absence of mutations by comparison
with published sequences of H37Rv using the SeqMan alignment application of
the DNAStar Lasergene (version 8.0) program. Genotypic data for each isolate
at a particular locus were recorded in a Microsoft Office Excel 2003 spreadsheet.
Mixed peaks within a chromatogram were treated as being true if they were
reproducible in both the forward and reverse directions. The genetic data, spo-
ligotype results, and phenotypic data sets were then compiled in separate tables
within a Microsoft Office Access 2003 database and analyzed further with the
analysis function of Epi Info (version 3.5.1, 2008) software. Repeat testing
was performed on any isolate for which the genotypic result predicted resis-
tance but it was determined to be susceptible by the initial DST. This was true
for all drugs except PZA, due to variability in testing methods. Sensitivity and
specificity values were determined by comparison of the genotypic and phe-
notypic data sets.
RESULTS
Drug susceptibility testing and DNA sequencing. We ana-
lyzed 314 clinical isolates, including 60 from the WHO molec-
ular proficiency testing panels (2007 to 2008) and 254 from the
isolates stored at CDC (2000 to 2008). The isolates were re-
ceived from both U.S. (134 isolates; 43%) and non-U.S. (167;
53%) laboratories (geographic origin data were unavailable for
72 [23%] of the study isolates). Spoligotyping was performed
on the entire study set and determined that the most highly
represented families were the East Asian Beijing (127; 40.4%),
EuroAmerican (54; 17.2%), and EuroAmerican (Latin Amer-
ican and Mediterranean; 44; 14.0%). The IndoOceanic (18;
5.7%), East African Indian (7; 2.2%), EuroAmerican S (2;
0.6%), IndoOceanic India (1; 0.3%), and IndoOceanic Manila
(1; 0.3%) lineages were less represented (see Table S2 in the
supplemental material). Spoligotyping also revealed one M.
bovis isolate, 14 unknown spoligotype patterns, and three iso-
lates for which no result could be obtained (see Table S2 in the
supplemental material).
In addition to spoligotyping, phenotypic DST was completed
on all study isolates for six of the nine study drugs: RIF, INH,
CIP, KAN, CAP, and EMB. Testing was not completed on all
isolates for OFX (69; 21.9%), as it was not fully incorporated
into the CDC testing regimen until 2002; AMK (1; 0.3%), due
to a lack of growth from one original isolate, and PZA (122;
39%), due to a lack of testing for the WHO panel samples, as
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well as variation in CDC testing methods. Of the tested iso-
lates, 55 (16%) were susceptible to all study antibiotics, 163
(52%) were found to be MDR M. tuberculosis, and 10 (3%)
were determined to be XDR M. tuberculosis. The remaining 96
(29%) isolates included 19 (19.8%) monoresistant and 77
(80.2%) poly-drug-resistant isolates. DNA sequencing of the
nine loci in the study was 90.8% sensitive and 94.7% specific
for the detection of MDR M. tuberculosis isolates (Table 1) and
was 40.0% sensitive and 99.3% specific for the detection of
XDR M. tuberculosis isolates. DST and DNA sequencing
agreement varied for each locus and drug combination. When-
ever discordance between the two methods was detected, re-
peat testing was initiated for both techniques with all drugs
except PZA. If the repeat test results were in conflict with the
original data, a third round of testing was completed, with
the final value representing two out of the three iterations. The
only exceptions to this practice were the WHO panel isolates,
which were not subjected to repeat drug susceptibility testing.
Results for each of the nine drugs and their respective loci are
presented individually in the succeeding sections.
Rifampin and rpoB. Since the majority of strains resistant to
RIF harbor mutations within the RRDR of rpoB, this region
and flanking sequence were analyzed in this study. A total of
174 (55.4%) of the isolates were RIF resistant and included
163 MDR and 10 XDR M. tuberculosis isolates. The vast ma-
jority (169/175; 97.1%) of RIF-resistant isolates harbored at
least one mutation within the RRDR of rpoB, while 5 of the
resistant isolates lacked such a mutation (see Table S3 in the
supplemental material). A total of 26 nonsynonymous single
nucleotide polymorphisms (nSNPs), one 3-bp insertion, and a
silent mutation were identified among the study isolates. Fif-
teen of the resistant isolates harbored two missense mutations
represented by 12 unique pairs and 3 of the same combination
(Gln513His and Leu533Pro). In seven of the double mutants,
one of the mutations occurred outside the RRDR, while the
other mutation was located within that region. One isolate with
a silent mutation (Phe514Phe) also had a Ser531Leu substitu-
tion. When all mutations, both single and double, are consid-
ered, a total of 31 rpoB genotypes were identified (see Table S3
in the supplemental material). The three most frequently ob-
served mutations accounted for 75% of the RIF-resistant iso-
lates in this study (Table 2). Among the 140 RIF-susceptible
isolates, 9 were found to have a mutation within the rpoB gene,
including 4 isolates with a His526Asn substitution, 2 each with
either a His526Leu or Leu533Pro substitution, and 1 with a
Leu511Pro substitution. Detection of nSNPs within the RRDR
of rpoB exhibited a sensitivity and specificity of 97.1% and
TABLE 1. Number of clinical M. tuberculosis isolates stratified by resistance to nine antibiotics, mutation, and validity values

















RIF rpoB 169a 5 9 131 97.1 93.6
INH katG 181 31 0 102 85.4 100
inhA 35 177 0 102 16.5 100
katG and/or inhA 192 20 0 102 90.6 100
EMB embB 121b 33c 11d 149e 78.6 93.1
PZAf pncA 55 10 15g 109h 84.6 85.8
CIP and OFX gyrA 80 18 5 211 81.6 97.7
KAN rrs 64 47 2 201 57.7 99.0
eis 32 79 6 197 28.8 97.0
rrs or eis 96 15 8 195 86.5 96.1
AMK rrs 63 7 3 241 90.0 98.8
CAP rrs 38 31 28 217 55.1 88.6
tlyA 7 62 3 242 10.1 98.8
rrs and/or tlyA 42i 27 31 214 60.9 87.3
MDR (RIF and INH) rpoB and katG and/or inhA 148 15 NAj NA 90.8 94.7
a Includes 15 isolates with two mutations.
b Excludes 3 isolates in which only the Glu378Ala polymorphism was identified.
c Includes 3 isolates with only the Glu378Ala polymorphism.
d Excludes 16 isolates in which only the Glu378Ala polymorphism was identified.
e Includes 16 isolates with only the Glu378Ala polymorphism.
f Includes 192 isolates with drug susceptibility results.
g Excludes 3 isolates with silent mutations.
h Includes 3 isolates with silent mutations.
i Includes 2 isolates with a mutation in each locus.
j NA, not applicable.
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93.6%, respectively, for predicting phenotypic RIF results (Ta-
ble 1).
Isoniazid and katG and inhA. INH is classified as a prodrug
and is activated by the catalase-peroxidase encoded by katG.
Mutations within katG, especially at codon 315, can result in
loss of catalase activity and INH resistance. The target of
activated INH is enoyl-acyl carrier protein reductase (InhA),
and increased expression of inhA as a result of promoter mu-
tations leads to resistance via a drug titration mechanism. We
sequenced a region of katG encompassing codon 315 and the
inhA promoter because it has been well established that most
INH-resistant isolates possess mutations in one or both of
those regions. A total of 212 isolates were resistant to at least
0.2 g/ml INH, of which 192 (90.5%) contained a katG and/or
an inhA mutation (see Table S4 in the supplemental material).
Twenty-four (11.3%) of the resistant isolates harbored a mu-
tation in both loci, while 157 (81.8%) had only katG mutations
and 11 (5.7%) had only inhA mutations. The remaining 20
(9.4%) INH-resistant isolates were wild type in both loci. As
anticipated, the most prevalent katG alteration was the substi-
tution of threonine for serine at amino acid 315. This amino
acid substitution resulted from a codon change from AGC to
ACC in 165 (86%) isolates and to ACA in 9 (5%) isolates.
Other katG codon 315 mutations observed were substitution
with asparagine (AAC) in two isolates and isoleucine (ATC) in
one isolate. Three isolates had an Ile335Val change in combi-
nation with a Ser315Thr substitution. One resistant isolate had
a single katG missense mutation in a codon other than 315,
resulting in the substitution of serine (AGT) for glycine (GGT)
at codon 273. No katG mutations were found in the 102 INH-
susceptible isolates. Detection of an nSNP within the region of
katG analyzed exhibited a sensitivity of 85.4% and a specificity
of 100% (Table 1).
Thirty-five of the INH-resistant isolates had a mutation
within the inhA promoter, 32 (91.4%) of which were a cytosine-
to-thymine transition at the nucleotide positioned 15 bases
upstream of the start codon [C(15)T] (see Table S4 in the
supplemental material). The remaining three INH-resistant
isolates had a transition from thymine to cytosine 8 nucleotide
bases upstream from the start codon [T(8)C]. Twenty-one of
the isolates with a C(15)T mutation also had a katG
Ser315Thr substitution. All 21 of these isolates were resistant
to 5 g/ml isoniazid. None of the INH-susceptible isolates
possessed an inhA mutation. For the 20 INH-resistant isolates
with no katG or inhA promoter mutation, the first 135 codons
of the inhA structural gene were sequenced, and all were wild
type. On its own, the detection of an inhA mutation was 16.5%
sensitive and 100% specific (Table 1). When the results for
both katG and inhA are considered together, the assay sensi-
tivity improves from 85.4% to 90.6% and the specificity re-
mains 100% (Table 1).
Ethambutol and embB. EMB targets embB-encoded arabi-
nosyl transferase and thereby inhibits arabinogalactan synthe-
sis. Mutations within a region of embB designated the ERDR
were analyzed, since mutations in this region have been re-
ported in 50 to 60% of EMB-resistant isolates. In this study, a
total of 154 isolates were resistant to 5 g/ml EMB, of which
124 (80.5%) had at least one mutation within the region of
embB examined. Among the 160 EMB-susceptible isolates, 27
had an embB mutation. In total, 158 embB nSNPs were iden-
tified, consisting of 16 unique mutations within 11 different
codons (see Table S5 in the supplemental material). One silent
mutation occurred at leucine residue 355. Eighty-five (53.8%)
of the embB single mutations occurred within codon 306
(ATG), resulting in methionine being replaced by valine
(GTG), isoleucine (ATA), or leucine (CTG) in 53, 29, and 3
isolates, respectively. All 53 isolates with an embB Met306Val
substitution were EMB resistant, as were the 3 isolates with
Met306Leu. In contrast, 5 (17.2%) of the 29 isolates har-
boring the Met306Ile allele were EMB susceptible. Other
substitutions found within EMB-susceptible isolates include
Ala313Val (two isolates) and Asp354Ala (two isolates). The
GAC-to-GCC codon change producing the Asp354Ala substi-
tution also occurred in nine EMB-resistant isolates. Twenty-
two isolates had an embB mutation, resulting in the substitu-
tion of alanine (GCG) for glutamic acid (GAG) at residue 378
(Glu378Ala), and in 18 of those isolates this was the only embB
mutation. Sixteen of the isolates with only the EmbB
Glu378Ala substitution were EMB susceptible, and nine of
those were pansusceptible. Four EMB-resistant isolates had a
Glu378Ala substitution in conjunction with another embB mu-
tation: two with Met306Val and one each with Met306Ile and
Asp328Tyr. Two isolates with only the Glu378Ala substitution
in EmbB were EMB resistant. Our finding that 20 (91%) of the
isolates with an embB Glu378Ala substitution either were
EMB susceptible or had an additional embB mutation to ex-
plain the isolate’s resistance leads us to conclude that this
TABLE 2. Most frequently identified mutations within nine M.
tuberculosis drug resistance-associated loci among isolates
resistant to that antibiotic for which each locus serves







RIF rpoB Ser531Leu 108 62.1
His526Tyr 20 11.5
Asp516Val 12 6.9
INH katG Ser315Thr 176 83.0
inhA C(15)T 32 15.1
T(8)C 3 1.4
EMB embB Met306Val 55 42
Met306Ile 27 20.6
PZA pncA Frameshifts 15 23.1
Gln10Pro 4 6.2
CIP and OFX gyrA Asp94Gly 28 28.6
Asp90Val 25 25.5
Asp94Ala 10 10.2
KAN rrs A1401G 62 55.9
eis G(10)A 14 12.6
C(14)T 11 9.9
AMK rrs A1401G 62 88.6
CAP rrs A1401G 34 49.3
tlyA Various NAb NA
a Compared with the total number of isolates resistant to drug of interest.
b NA, not applicable.
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mutation represents a naturally occurring lineage marker and
does not confer EMB resistance. In fact, 18 of the 22 isolates
harboring the mutation were determined to belong to the
IndoOceanic lineage. If the Glu378Ala substitution is treated
as a naturally occurring polymorphism, the detection of embB
nSNPs for predicting EMB phenotypic results exhibits a sen-
sitivity of 78.6% and specificity of 93.1% (Table 1).
Pyrazinamide and pncA. PZA is a prodrug that requires
conversion to its active metabolite by the pncA-encoded en-
zyme, pyrazinamidase. Some mutations within pncA are asso-
ciated with loss of enzyme activity and both are, in turn, highly
correlated with PZA resistance. The entire pncA open reading
frame and additional upstream sequence were analyzed for 249
of the study isolates (see Table S1 in the supplemental mate-
rial). DNA sequencing was not completed for the 60 WHO
isolates and failed to produce data of acceptable quality for five
CDC isolates after three attempts each. PZA susceptibility and
pncA sequencing results were available for 192 isolates, of
which 65 were PZA resistant. Among the resistant isolates, 55
(84.6%) possessed a pncA mutation and 10 retained the wild-
type sequence, while in the case of the 127 PZA-susceptible
isolates, 109 (88.6%) lacked a pncA mutation, while 15 har-
bored mutations (see Table S6 in the supplemental material).
Considering all 246 isolates with pncA sequence results, 116
possessed a pncA mutation. These mutations consisted of 79
unique alterations distributed throughout the gene and regu-
latory region. The majority (84/116; 72.4%) of these were
nSNPs, but insertions (n  10 isolates), deletions (n  9), and
nonsense (n  6), synonymous (n  3), and putative regulatory
(n  4) mutations were also identified. The most frequent
mutation was a Thr47Ala change, found in five isolates. Three
isolates had a synonymous mutation at serine residue 65.
Three methods of PZA susceptibility testing were used in
this study, with 13 isolates being tested by the Bactec and agar
proportion methods, 7 by the Bactec and MGIT methods, and
the remainder by one of the three techniques. No isolates were
tested by both the MGIT and agar proportion methods. When
the test sensitivity and specificity for the three methods are
calculated separately and independently, the values are 89.2%
and 94.4%, respectively, for the Bactec method (n  112),
83.3% and 83.9%, respectively, for the agar proportion meth-
ods (n  49), and 93.3% and 79.4%, respectively, for the
MGIT method (n  51). Two of the isolates tested by both the
Bactec and MGIT methods had discordant results, while
the results for all those tested by both the Bactec and agar
proportion methods were concordant. In the two discrepant
isolates, the Bactec result was used in calculating the test
accuracy values. Cumulatively, the identification of nSNPs
within pncA exhibited a sensitivity and specificity of 84.6% and
85.8%, respectively (Table 1).
Fluoroquinolones and gyrA. Resistance to the FQs has been
attributed to mutations within subunit A of DNA gyrase (en-
coded by gyrA), which prevent the drugs from effectively bind-
ing the gyrase (44). In this study, we analyzed the QRDR of
gyrA, which is known to house the majority of mutations asso-
ciated with resistance (33). DST data were available for CIP
(314 isolates) and OFX (245 isolates). A total of 98 isolates
were resistant to either CIP (n  94) or OFX (n  83),
including 79 resistant to both drugs. Four isolates were resis-
tant only to OFX, 14 isolates were resistant to CIP and did not
have DST results for OFX, and 1 isolate was resistant to CIP
but susceptible to OFX. Out of the total number of resistant
isolates, 80 (90%) were found to harbor mutations within the
QRDR of gyrA (see Table S7 in the supplemental material).
The most common mutations were observed at codon 94 (n 
49), where the wild-type aspartic acid (GAC) was replaced with
a glycine (D94G; n  26), an alanine (D94A; n  11), an
asparagine (D94N; n  10), or a tyrosine (D94Y; n  2) (Table
2). The Asp94Gly mutation was also found in two combina-
tions, once with an Ala90Val mutation and once with a
Ser91Pro mutation. In addition, 26 isolates harbored the
Ala90Val mutation, and of these, 25 were FQ resistant, while
1 was susceptible. Other mutations associated with the FQ-
resistant isolates included Asp89Asn (n  1), Asp89Gly (n 
1), Gly88Cys (n  2), and Ser91Pro (n  2). The two mutations
at codon 89 were not previously reported in the literature. The
remaining 18 FQ-resistant isolates were determined to be wild
type for the QRDR of gyrA.
Of the 161 isolates determined to be susceptible to both CIP
and OFX, one contained the resistance-associated Ala90Val
mutation and four harbored the Thr80Ala (ACC 3 GCC)
mutation, which has previously been reported to provide weak
FQ hypersusceptibility (2). All other susceptible isolates were
determined to be wild type for the QRDR of gyrA. When the
genotypic data for gyrA were compared with the drug susceptibil-
ity results for the FQ, the sensitivity and specificity values were
determined to be 81.6% and 97.7%, respectively (Table 1).
Amikacin and rrs. Mutations associated with resistance to
AMK are located within rrs, which encodes the ribosomal 16S
rRNA (1). In this study, we analyzed a 516-bp region of rrs that
contains the most common resistance-associated mutations.
Genotypic and phenotypic data were available for 313 study
isolates, where 70 (22.4%) were resistant to 4 g/ml amikacin
and 243 (77.6%) were AMK susceptible. All of the AMK-
resistant isolates were found to be cross-resistant to either
KAN (32; 45.7%) or KAN and CAP (38; 54.3%). Sixty-three
(90%) of the resistant isolates were found to have rrs muta-
tions, including 61 with A1401G resistance-associated muta-
tions, 1 with the resistance-associated T1322C and A1401G
combination of mutations, and 1 with a G1484T resistance-
associated mutation (see Table S8 in the supplemental mate-
rial).
Of the 243 AMK-susceptible isolates, 240 were determined
to be wild type for rrs. One isolate contained a C1402T muta-
tion, which has been reported to be associated with AMK
susceptibility, and 2 isolates (representing 1 WHO duplicate)
contained a previously unreported A1196G mutation (18) (see
Table S8 in the supplemental material). Final comparison of
the genotypic and phenotypic data produced a sensitivity value
of 90% and a specificity value of 98.8% (Table 1). If the values
are calculated using only the A1401G mutation, the sensitivity
decreases minimally to 87.1% and the specificity increases to
100%.
Kanamycin and rrs and eis. Known mechanisms of KAN
resistance are caused by mutations in rrs or the promoter
region of eis which prevent the drug from inhibiting translation
(15, 45). In this study, a 516-bp region of the open reading
frame of rrs and the promoter region of eis were analyzed, as
they are known to contain resistance-associated mutations. Of
the 314 isolates, 111 (35.4%) were resistant to KAN, and 96
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(86.5%) of these isolates contained mutations within the rrs
(64; 57.7%) or eis (32; 28.8%) regions of interest (see Tables
S8 and S9 in the supplemental material). None of the isolates
contained mutations within both loci. The most frequent rrs
mutation was A1401G (62; 96.9%), which was observed in 61
isolates as a single mutation and in 1 isolate with the previously
unreported T1322C substitution (Table 2). The isolate harbor-
ing the A1401G and T1322C double mutation was also resis-
tant to amikacin but susceptible to capreomycin. Other rrs
polymorphisms included the resistance-associated C1402T
(n  1) and G1484T (n  1) mutations (18). Mutations within
the promoter region of eis included the resistance-associated
G(10)A (14; 43.8%), C(14)T (10; 31.3%), G(37)T (5;
15.6%), and C(2)A-C(14)T combination mutations. One
isolate harbored a C(12)T mutation, which has been associ-
ated with susceptibility to KAN (45).
A total of 203 (64.7%) isolates were KAN susceptible, of
which 195 (96.1%) were wild type for both the rrs and eis loci,
and 8 (3.9%) harbored mutations within either rrs (n  2) or
eis (n  6). None of the isolates had mutations within both loci.
The two isolates with mutations within rrs represented one
WHO duplicate and contained a previously unreported
A1196G mutation. The seven eis mutations included four pro-
moter polymorphisms and three amino acid substitutions.
The promoter mutations included three susceptibility-asso-
ciated C(12)T substitutions and one resistance-associated
G(10)A substitution. The open reading frame mutations
were observed in two isolates, with one harboring a silent
Pro90Pro substitution and the other having a combination
of a silent Ser48Ser substitution and a Met100Thr polymor-
phism.
Upon comparison of the genotypic and phenotypic data, rrs
was found to be 57.7% sensitive and 99% specific, while eis was
28.8% sensitive and 97.0% specific (excluding the silent muta-
tions) (Table 1). Upon combination of the data sets for both
loci, the sensitivity value increased to 86.5% and the specificity
value changed to 96.1% (Table 1).
Capreomycin and rrs and tlyA. Resistance to CAP is associ-
ated with mutations within rrs and tlyA genes in M. tuberculosis
(19, 34). In this study, a 516-bp region of rrs and the entire
open reading frame of tlyA were analyzed, as these areas are
known to house the majority of resistance-associated muta-
tions. Of the 314 total clinical isolates in this study, 69 (22%)
were resistant to CAP, including 29 susceptible to AMK or
KAN. Of the 69 resistant isolates, 42 (60.9%) contained mu-
tations within rrs (n  38) or tlyA (n  7), 3 contained muta-
tions in both genes, and 27 (39.1%) were wild type for both loci
(see Tables S8 and S10 in the supplemental material). The
most frequent rrs polymorphism was the A1401G mutation,
which was found in 34 (89.5%) of the resistant isolates (Table
2). Other rrs mutations included two novel A1196G mutations
(WHO duplicate isolates), one resistance-associated C1402T
mutation, and one resistance-associated G1484T mutation
(18). Mutations within the tlyA open reading frame included
two amino acid substitutions at codon 236, Asp236Lys, one
previously unreported Asp57His mutation, two GC insertions
at nucleotide 202 (WHO duplicate isolates), and two
Gly196Glu mutations (WHO duplicate isolates).
A total of 245 (78%) study isolates were CAP susceptible,
with 31 (12.7%) containing mutations in either rrs or tlyA and
214 (87.3%) being wild type for both loci. The mutations har-
bored by CAP-susceptible strains were located in either rrs or
tlyA, with no overlap between the two genes. For isolates with
polymorphisms within rrs, a total of 28 (90.3%) isolates had the
A1401G mutation, which occurred as single events in 27 iso-
lates and together with a T1322C substitution in 1 isolate. The
tlyA mutations included a Gly195Asp mutation, a Leu164Ser
mutation, and a silent mutation at codon 28.
Comparison of the drug susceptibility data and the genotypic
data for CAP (rrs only) produced a sensitivity value of 55.1%
and a specificity value of 88.6% (Table 1). Data for tlyA with-
out combination with rrs resulted in a 10.1% sensitivity and a
98.8% specificity (excluding the silent mutation) (Table 1).
Upon combination of rrs and tlyA data, the overall sensitivity
and specificity values change to 60.9% and 87.3%, respectively
(Table 1).
Cross-resistance among the second-line injectable drugs
AMK, KAN, and CAP is well documented and also supported
by this study (1, 18, 34, 36). Of the 111 KAN-resistant isolates,
38 (34.2%) were KAN monoresistant, 38 (34.2%) were cross-
resistant with both AMK and CAP, 32 (28.8%) were cross-
resistant with only AMK, and 2 (1.8%) were cross-resistant
with only CAP. All of the AMK-resistant isolates were cross-
resistant with either KAN or KAN and CAP, but none were
resistant to only AMK. Of the 69 CAP-resistant isolates, only
29 (42%) were CAP monoresistant, although the remaining 40
were cross-resistant with either KAN or KAN and AMK. The
38 KAN-, AMK-, and CAP-resistant isolates included 35 with
mutations within rrs, 1 with a combination rrs and tlyA muta-
tions, and 3 that were wild type for all loci (see Table S11 in the
supplemental material). The isolates with resistance-associated
rrs mutations included 34 with A1401G mutations and 1 with a
G1484T mutation. The tlyA mutation resulted in the Asp57His
amino acid change in combination with an A1401G rrs substi-
tution (see Table S11 in the supplemental material). The 32
KAN- and AMK-resistant isolates included 28 with rrs muta-
tions (27 with A1401G single mutations and 1 with the T1322C
and A1401G combination), 1 with an eis mutation [C(14)T],
and 3 of the wild type (see Table S11 in the supplemental
material). Lastly, the two isolates resistant to both KAN and
CAP were wild type for both eis and tlyA, while one contained
a C1402T mutation within rrs (see Table S11 in the supple-
mental material).
DISCUSSION
The results of this study demonstrate the utility of detection
of mutations associated with drug resistance to rapidly and
accurately determine the drug susceptibility of M. tuberculosis
complex isolates. This study also demonstrates the advantages
of DNA sequencing over methods that use DNA probes to
detect deviation from the wild-type sequence or a limited set of
specific mutations, since several specific mutations identified in
this study were not associated with drug resistance. Each re-
sistance-associated locus examined has its own unique proper-
ties which must be taken into consideration when the molec-
ular drug sequencing results are interpreted.
The molecular mechanism of resistance to RIF is the most
completely understood of the resistance mechanisms of all the
drugs used in the treatment of tuberculosis, and it has been
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well established that mutations within the RRDR of rpoB
occur in 95% or more of RIF-resistant isolates. Within the
RRDR, three specific mutations predominate (Ser531Leu,
His526Tyr, and Asp516Val), presumably because these muta-
tions minimally impact the fitness of the bacilli (16, 29). In this
study, 140 of the 174 (80.5%) RIF-resistant isolates harbored
one of these three rpoB mutations. However, many other
RRDR mutations have been described, including 25 within our
study (see Table S3 in the supplemental material). Since these
other mutations are far less frequently encountered, their
association with RIF resistance has not been well estab-
lished. Some of these rpoB mutations, including Leu511Pro,
Asp516Tyr, His526Leu/Ser, and Leu533Pro, are associated
with discordant susceptibility test results (37). In a previous
study, 11 isolates harboring these mutations were classified
RIF susceptible by either the Bactec 460 TB or Bactec 960
MGIT system, while only 1 was susceptible by the proportion
method on Löwenstein-Jensen medium and only 2 were sus-
ceptible on Middlebrook 7H10 agar (37). The authors pro-
posed that these mutations could confer low-level but clinically
relevant RIF resistance (37). Others have considered isolates
harboring the Leu533Pro substitution to be susceptible (17,
25). In this study, the His526Asn, His526Leu, and Leu533Pro
mutations were identified in eight susceptible and eight resis-
tant isolates. Four of the eight resistant isolates contained
other resistance-associated rpoB mutations. These data weakly
support the association of these mutations with low-level re-
sistance. However, further studies are required to definitively
characterize their role in RIF resistance. The relative rarity of
these mutations may be partially attributable to selection bias,
as most studies have examined primarily or exclusively RIF-
resistant isolates. With increased use of genotypic methods to
diagnose RIF resistance, these mutations may be more fre-
quently observed, and subsequently, their clinical and epide-
miological significance may be better understood. The speci-
ficity of DNA sequencing as a diagnostic tool will increase,
should future research establish that certain RRDR mutations
do not impart a clinically relevant level of RIF resistance. The
possibility that such mutations exist has important ramifica-
tions for methods which detect the presence of any mutation
and not the mutation of interest.
The mode of action of isoniazid, though extensively investi-
gated, remains incompletely understood. Several different loci
are known to be involved in resistance, especially katG and
inhA. Mutations in codon 315 of katG and the inhA promoter
are proven mechanisms of INH resistance. None of the INH-
susceptible isolates in this study had a mutation in either katG
codon 315 or the inhA promoter, making the test 100% spe-
cific. Nineteen of the INH-resistant isolates were wild type at
both these locations and also in the region of the inhA struc-
tural gene where resistance-associated mutations have been
reported (data not shown) (3, 4). Although mutations in other
loci, such as ndh and ahpC, may account for the INH-resistant
phenotype in some of these isolates, we chose not to sequence
these loci because there are very limited data on their role in
INH resistance.
Until recently, the significance of mutations within the M.
tuberculosis embB gene, especially those at codon 306, had
been controversial because such mutations had been reported
in both EMB-susceptible and -resistant isolates (11, 21, 30).
Allelic exchange experiments have now convincingly shown
that mutations at embB codons 306, 406, and 497 confer EMB
resistance (27, 28, 32). In those earlier reports of EMB-suscep-
tible isolates harboring embB mutations, the drug susceptibility
results were presumably inaccurate. Conventional culture-based
methods of EMB susceptibility testing are notoriously problem-
atic (14). The allelic exchange studies demonstrated that the mu-
tants with Met306Val and Met306Leu mutations had EMB MICs
well above the critical concentration used for drug susceptibility
testing, and indeed, we found that all of those isolates with only a
Met306Val (n  53) or Met306Leu (n  3) substitution were
EMB resistant. In contrast, MICs for the mutants with the
Met306Ile mutation were only modestly higher than the critical
concentration, a confounding circumstance that could result in
false-susceptible EMB testing results. This expectation is sup-
ported by our finding that 5 of the 29 isolates possessing only a
Met306Ile substitution were EMB susceptible.
The third most frequent embB substitution in this study was
Glu378Ala. This was the only embB mutation in 22 isolates, of
which 16 were EMB susceptible. This substitution was previ-
ously reported in a single isolate (26) and in combination with
an Asp299Glu substitution in two isolates (31), and in both
reports, the isolates were characterized to be EMB resistant.
The probable explanation for the paucity of reports of this
mutation is that prior studies have examined primarily EMB-
resistant strains. In this study, we examined a large number of
EMB-susceptible and pansusceptible isolates to more accu-
rately assess the drug susceptibility phenotype of the mutations
identified. Of the 22 isolates, 18 were determined to belong to
the IndoOceanic lineage by spoligotyping. Therefore, our data
indicate that the mutation resulting in the Glu378Ala substi-
tution is a naturally occurring polymorphism and possible lin-
eage marker that does not confer EMB resistance. Functional
genetic analysis of this mutation is needed to definitively vali-
date this conclusion.
We identified 20 different embB mutations or combination
of mutations, including the previously discussed Glu378Ala
mutation. This diversity of mutations gives DNA sequencing a
definite advantage over hybridization-based methods, particu-
larly given that a putative polymorphism occurs within the
ERDR. Although further functional genetic data are needed
to better define the phenotype of additional embB mutations,
complementing inherently problematic culture-based DST
with DNA sequencing would substantially improve diagnostic
accuracy.
The presence of a mutation within pncA has been shown to
correlate well with PZA resistance (22), and a diverse and
widely distributed array of pncA mutations has been reported
(29). We also found a diverse group of pncA mutations that
correlated well with PZA resistance. Conventional DST of
PZA is challenging and problematic due to the poor growth of
M. tuberculosis under the acidic conditions (pH 5.5 to 6.0)
required for optimal drug activity (13, 20). The good correla-
tion between the presence of a pncA mutation and PZA resis-
tance makes DNA sequencing of this gene a very useful
adjunctive diagnostic test. Unfortunately, the tremendous di-
versity of reported pncA mutations and the lack of any pre-
dominant mutations represent a substantial limitation. With-
out strong statistical evidence linking specific mutations with
PZA resistance, further experimental evidence is needed to
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determine which pncA mutations confer resistance. Mindful of
these limitations, the use of pncA sequencing in conjunction
with phenotypic PZA testing could aid in determining PZA
susceptibility. Additional studies to characterize the phenotype
of specific pncA mutations through the determination of MIC
values or functional genetics would greatly enhance the diag-
nostic value of pncA sequencing.
The FQs are known to be effective against M. tuberculosis by
targeting and inhibiting the essential bacterial enzyme DNA
gyrase (44). It has been well established that mutations within
gyrA, which encodes subunit A of the DNA gyrase, are often
associated with resistance (33, 35, 40). The most common
resistance-associated mutations within gyrA are found within
the QRDR at codons 94 and 90, as was the case with our study
(35, 40). In addition to the known mutations, we discovered the
novel Asp89Asn and Asp89Gly substitutions. Because these
mutations have not been previously reported, their association
with resistance is unknown. Lastly, 18 FQ-resistant isolates did
not harbor any mutations within the gyrA locus. These isolates
could be explained by mutations within the gyrB locus (unex-
amined in this study) or by unknown mechanisms of FQ resis-
tance.
The FQ-susceptible isolates harbored primarily wild-type
gyrA loci, with few exceptions. One isolate contained the resis-
tance-associated Ala90Val mutation, and repeat sequencing
confirmed the discordant result. However, repeat DST was
unable to be completed due to the lack of subsequent growth
from the original isolate, leaving the possibility of irreproduc-
ible phenotypic results. In addition, four FQ-susceptible iso-
lates harbored the Thr80Ala mutation, which has been re-
ported as providing a strain with increased susceptibility, and
are therefore not discordant (2).
Because resistance to one of the second-line injectable drugs
is part of the definition of XDR TB, the establishment of rapid
assays for detecting resistance to these drugs is of particularly
high importance. All of these drugs are known to target the
bacterial ribosome, and mutations within the 16S rRNA, en-
coded by rrs, are well established as being associated with
second-line drug resistance. Most of the resistance-associated
mutations within rrs are found within a 516-bp region of the
gene. In this study, rrs mutations associated with AMK-resis-
tant isolates included a large number of expected A1401G
mutations as well as a resistance-associated G1484T mutation.
Both of these mutations have been previously described as
playing a central role in AMK resistance (18). In addition to
the established mutations, we also discovered a previously un-
reported T1322C and A1401G combination of mutations in an
isolate resistant to AMK, KAN, and CAP. Since the T1322C
mutation has not been previously identified, its role in amino-
glycoside resistance is unclear, both as a lone mutation and in
combination with the A1401G substitution. However, its pres-
ence in an isolate that is 100% resistant to both KAN and
AMK suggests that it is associated with aminoglycoside resis-
tance. We did not detect any resistance-associated mutations
in the vast majority of AMK-susceptible isolates; however, one
contained the C1402T mutation for AMK susceptibility and
two harbored novel A1196G SNPs (18). Because the substitu-
tion was found only in susceptible isolates, it is unlikely that it
is associated with AMK resistance.
Alterations within the rrs locus also play a significant role in
KAN resistance, with the 65 detected RRDR mutations ac-
counting for 60% of substitutions within KAN-resistant iso-
lates (1, 15, 34). The detected A1401G, C1402T, and G1484T
mutations have all been well established as resistance-associ-
ated substitutions, leaving the novel A1401G and T1322C mu-
tation combination to be the only allele with unknown impli-
cations (18). Two study isolates that were both AMK and KAN
susceptible harbored previously unknown A1196G mutations,
suggesting that these substitutions do not confer resistance.
In addition to rrs, mutations within the promoter region of
eis, which encodes an aminoglycoside acetyltransferase, are
associated with low-level KAN resistance (45). In our survey,
we identified 38 eis mutations, including 3 previously unre-
ported substitutions. The most common previously reported
resistance-associated eis mutations included the G(10)A,
C(14)T, and G(37)T polymorphisms (45). Our study sup-
ports these findings, as they were also the most prominent in
our KAN-resistant isolates (see Table S9 in the supplemental
material). Also in agreement with the previous study was our
finding of the C(12)T mutation in a KAN-resistant isolate
and three KAN-susceptible isolates (see Table S9 in the sup-
plemental material). These data support the proposed hypoth-
esis that this mutation may result in an MIC value close to the
recommended critical concentration for testing KAN suscep-
tibility (45). As a result, the C(12)T mutation is considered a
polymorphism with little predictive value for KAN resistance.
It is also of note that we identified one G(10)A mutation in
a KAN-susceptible isolate from the 2008 WHO proficiency
testing panel. Because WHO isolates were not subjected to
repeat testing, this result remains unconfirmed and may be
explained by undetected low-level KAN resistance. Lastly, our
detection of the Ser48Ser and Met100Thr mutation combina-
tion within the open reading frame of eis is novel, and the
potential effects of open reading frame mutations on KAN
resistance are unknown. However, eis-mediated resistance is
due to promoter mutations that alter eis expression levels, and
the impact of open reading frame mutations on KAN resis-
tance would potentially require a separate mechanism.
Although the combination of mutations within rrs and eis
resulted in a relatively high specificity (86.5%), 15 KAN-resis-
tant isolates did not harbor mutations in either gene. Two of
these 15 isolates were determined to be KAN susceptible upon
repeat drug susceptibility testing, suggesting that they may
display a level of resistance close to the current testing con-
centration. Two of the wild-type isolates were duplicates of
each other from the 2008 WHO panel, thereby representing
one isolate whose DST result was not confirmed with repeat
testing. In addition, two isolates were susceptible to 5 g/ml
KAN with subsequent repeat testing and were therefore no
longer considered discordant. The nine remaining isolates
were confirmed to be discordant by repeat testing and exhib-
ited a range of resistance levels, suggesting that there remains
at least one unknown mechanism for KAN resistance (data not
shown).
Similar to KAN, resistance to the macrocyclic polypeptide
CAP is associated with mutations within two separate loci: rrs
and tlyA (19, 34, 36). Polymorphisms within the rrs locus affect
CAP binding to the ribosome, while those within tlyA prevent
necessary methylation of rRNA, rendering their ribosomes
CAP resistant (19). Common rrs mutations associated with
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CAP resistance include the prominent A1401G mutation and
the C1402T and G1484T mutations. Our study detected all of
these polymorphisms as well as two novel A1196G mutations,
whose role in aminoglycoside resistance is currently unknown.
Previous studies have often demonstrated a strong correlation
between the A1401G mutation and CAP resistance (10, 18,
39). However, other reports have found the same mutation in
isolates determined to be CAP susceptible (5, 9, 12, 38). In this
study, we detected a large number of A1401G mutations in
both CAP-resistant and CAP-susceptible isolates (see Table S8
in the supplemental material). The mutations were verified by
repeat DNA sequencing; however, the drug susceptibility test-
ing result was found to vary widely upon repeat testing. In fact,
select isolates were retested up to five times, with different
results obtained for each testing cycle (data not shown). These
data suggest that the CAP MIC value for isolates harboring the
A1401G mutation may be very close to the current recom-
mended critical concentration for testing CAP susceptibility on
7H10 agar. Previous studies may not have detected this varia-
tion due to relatively smaller study sizes, limited numbers of
susceptible isolates, or variation in CAP drug susceptibility
testing methods.
Mutations within tlyA are uncommon, possibly due to lim-
ited and local usage of CAP to treat M. tuberculosis infections
(5, 12, 39). Polymorphisms within tlyA in our study were less
common than those within rrs, with the total number account-
ing for 13% of study mutations associated with CAP resistance.
The addition of tlyA mutation data to rrs mutation data in our
study increased our sensitivity and specificity for CAP resis-
tance from 55.1% and 88.6% to 60.9% and 87.3%, suggesting
that tlyA currently plays a minor role in the detection of CAP
resistance and could be used sparingly as a resistance marker,
as long as usage of the drug remains low.
Cross-resistance between the second-line injectables has
been well documented and is further supported by our study
data (5, 18, 38). As expected, the ribosomal rrs mutation
A1401G was the most common polymorphism associated with
cross-resistance between KAN, AMK, and CAP, as well as
KAN and AMK (see Tables S8 and S11 in the supplemental
material). One isolate, resistant to both KAN and AMK, har-
bored an A14041G substitution in combination with a T1322C
mutation (see Tables S8 and S11 in the supplemental mate-
rial). Because the latter polymorphism has not been previously
described and resistance to both drugs can be explained by the
rrs substitution, association of this novel mutation with resis-
tance to either drug is unclear. It is worth noting that none of
the isolates were resistant only to AMK, suggesting that de-
tection of AMK resistance may be a greater indication of
second-line cross-resistance. Lastly, although there was a high
level of agreement between our genotypic and phenotypic data
for injectable cross-resistance, some isolates were wild type for
all resistance-associated alleles (see Table S11 in the supple-
mental material). This result suggests that there is still at least
one mechanism of second-line injectable drug cross-resistance
that has yet to be discovered.
There is a current need for the development of rapid mo-
lecular tests that detect mutations associated with drug resis-
tance in strains of M. tuberculosis. Conventional culture-based
techniques are technically demanding and have long turn-
around times. Molecular techniques, such as the Sanger-based
DNA sequencing method presented here, provide specific and
prompt strain resistance data that aid in the development of
appropriate antituberculosis treatment regimens. The develop-
ment of genetic assays requires the verification of molecular
data with respect to conventional drug susceptibility data. Here
we completed a comprehensive survey of nine loci known to
harbor mutations associated with resistance to both first-line
and second-line anti-TB drugs. The resultant genotypic data
set was compared with drug susceptibility data to determine
sensitivity and specificity values for each locus (Table 1). These
values served to verify the new CDC MDDR service and have
the potential to aid in the development of other, in-house
molecular assays. Developed genetic tests will inevitably pro-
duce more rapid results for drug-resistant isolates, which will
lead to faster identification of MDR and XDR strains, more
tailored treatment regimens, and a reduction in the transmis-
sion of TB.
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